Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

20 Apr 2020

Abstract excerpt

Abstract Purpose: We pursued genomic analysis of an exceptional responder with non–small cell lung cancer (NSCLC) through a multi-platform effort to discover novel oncogenic targets. Experimental Design: In this open-label, single-arm phase II study (NCT01829217), an enriched cohort of patients with advanced NSCLC was treated with the multi-kinase inhibitor sunitinib. The primary endpoint was objective response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32312893
DOI: 10.1158/1078-0432.ccr-20-0397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung CancerPMID 32312893Read ↗

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.Semantic proximity Read ↗

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.Semantic proximity Read ↗

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screeningSemantic proximity Read ↗

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.Semantic proximity Read ↗

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome AtlasSemantic proximity Read ↗

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.Semantic proximity Read ↗

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Semantic proximity Read ↗

What have we learned from exceptional tumour responses?: Review and perspectives.Semantic proximity Read ↗

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.Semantic proximity Read ↗

Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editingSemantic proximity Read ↗

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.